Influence of three booster doses hepatitis B vaccine on the persistence of immune-protection among infants with normal and high antibody response to primary vaccination: a matched case-control study.

Yi Feng; Jingjing Lyu; Jiaye Liu; Bingyu Yan; Lizhi Song; Xiaofeng Liang; Li LI; Guomin Zhang; Fuzhen Wang; Li Zhang; Aiqiang XU

Return

Influence of three booster doses hepatitis B vaccine on the persistence of immune-protection among infants with normal and high antibody response to primary vaccination: a matched case-control study.

VernacularTitle:乙型肝炎疫苗初次免疫正常应答和高应答新生儿在幼儿期加强免疫对免疫保护持久性影响的配对病例对照研究
Author: Yi FENG ¹ ; Jingjing LYU ¹ ; Jiaye LIU ¹ ; Bingyu YAN ¹ ; Lizhi SONG ¹ ; Xiaofeng LIANG ² ; Li LI ³ ; Guomin ZHANG ³ ; Fuzhen WANG ³ ; Li ZHANG ¹ ; Aiqiang XU ¹
Author Information

1. Shandong Provincial Center for Disease Control and Prevention, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Shandong Province, Jinan 250014, China.
2. Chinese Center for Disease Control and Prevention, Beijing 102206, China.
3. National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Publication Type:Journal Article
MeSH: Antibody Formation; Case-Control Studies; Child; Hepatitis B; prevention & control; Hepatitis B Antibodies; blood; immunology; Hepatitis B Surface Antigens; immunology; Hepatitis B Vaccines; administration & dosage; immunology; Hepatitis B virus; Humans; Immunization, Secondary; Infant; Prevalence; Treatment Outcome; Vaccination
From: Chinese Journal of Epidemiology 2016;37(4):460-463
CountryChina
Language:Chinese
Abstract:
OBJECTIVETo examine the influence of three-booster-doses hepatitis B vaccines on children with normal and high antibody response to primary vaccination.
METHODSAntibody against hepatitis B surface antigen (anti-HBs) were detected after primary vaccination and children with normal or high response to hepatitis B primary vaccination at infancy, were identified. Children who were given three booster doses were selected to form the booster group and who were given no booster dose were 1∶1 matched with the same gender and residence to form the control group. Blood samples were obtained from all the participants and tested for anti-HBs and anti-HBc, 5 years after the primary vaccination.
RESULTSThe positive rates of anti-HBs response to primary vaccination were 97.39% (224/230, 95% CI: 94.41%-99.04%) in the booster group and 53.91% (124/230, 95% CI: 47.24%-60.48%) in the control group (P<0.05), 5 years after the primary vaccination. Geometric mean concentration (GMC) of anti-HBs were 1 140.02 (887.46-1 464.46) mIU/ml in the booster group and 11.53 (8.73-15.23) mIU/ml in the control group (P<0.05). The prevalence rates of breakthrough HBV infection were 0.87% (2/230) in the booster group and 2.17%(5/230) in the control group (P>0.05). RESULTS from the multivariable analysis showed that the booster doses (OR=38.75, 95%CI: 16.23-92.54) and the level of anti-HBs after the primary vaccination (OR =3.06, 95%CI:1.51-6.17) were independently associated with the positive rates of anti-HBs, 5 years after the primary vaccination (P<0.05).
CONCLUSIONPrograms with three booster doses to children that showing normal and high antibody response to primary vaccination could improve the persistence of anti-HBs but possibly would not be able to prevent the HBV infection.